GC
ACHN

Globeflex Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Globeflex Capital’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-87,000
Closed -$359K – 594
2016
Q4 		$359K Hold
87,000
– – 0.09% 300
2016
Q3 		$705K Sell
87,000
-200
-0.2% -$1.7K 0.18% 208
2016
Q2 		$680K Hold
87,200
– – 0.19% 202
2016
Q1 		$673K Buy
+87,200
New +$639K 0.18% 196

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Globeflex Capital's ACHN Position: Q1 2017 in Review

Globeflex Capital sold out of Achillion Pharmaceuticals (ACHN) in Q1 2017, closing a stake of 87,000 shares — an estimated $359K sold.

Globeflex Capital first reported a position in ACHN in Q1 2016 and held it in 4 quarters. The position peaked at $705K in Q3 2016. 130 funds tracked by Wall St. Rank hold ACHN as of Q1 2017.

  • Globeflex Capital reported no remaining Achillion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Globeflex Capital sold 87,000 Achillion Pharmaceuticals shares in Q1 2017, an estimated $359K.
  • Globeflex Capital first reported a position in Achillion Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Globeflex Capital's Achillion Pharmaceuticals position peaked at $705K in Q3 2016.
  • 130 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2017.

Based on Globeflex Capital's 13F filing for Q1 2017, filed 12 May 2017.